Nanobiotix (NBTX) Current Deferred Revenue: 2021-2025
- Nanobiotix's Current Deferred Revenue rose 178.12% to $40.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $40.9 million, marking a year-over-year increase of 178.12%. This contributed to the annual value of $19.3 million for FY2024, which is 1.21% down from last year.
- According to the latest figures from Q2 2025, Nanobiotix's Current Deferred Revenue is $40.9 million, which was up 111.70% from $19.3 million recorded in Q4 2024.
- Nanobiotix's 5-year Current Deferred Revenue high stood at $40.9 million for Q2 2025, and its period low was $14.7 million during Q2 2024.
- For the 3-year period, Nanobiotix's Current Deferred Revenue averaged around $23.6 million, with its median value being $19.4 million (2023).
- In the last 5 years, Nanobiotix's Current Deferred Revenue fell by 0.68% in 2024 and then soared by 178.12% in 2025.
- Nanobiotix's Current Deferred Revenue (Quarterly) stood at $18.9 million in 2021, then reached $19.5 million in 2023, then fell by 0.68% to $19.3 million in 2024, then soared by 178.12% to $40.9 million in 2025.
- Its Current Deferred Revenue stands at $40.9 million for Q2 2025, versus $19.3 million for Q4 2024 and $14.7 million for Q2 2024.
